<bill session="118" type="h" number="3839" updated="2024-07-24T15:21:45Z">
  <state datetime="2023-06-06">REFERRED</state>
  <status>
    <introduced datetime="2023-06-06"/>
  </status>
  <introduced datetime="2023-06-06"/>
  <titles>
    <title type="display">To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.</title>
  </titles>
  <sponsor bioguide_id="D000628"/>
  <cosponsors>
    <cosponsor bioguide_id="K000382" joined="2023-06-06"/>
  </cosponsors>
  <actions>
    <action datetime="2023-06-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-06-06" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-06-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="118" type="h" number="3561" relation="unknown"/>
    <bill session="118" type="s" number="775" relation="unknown"/>
    <bill session="118" type="s" number="1114" relation="unknown"/>
    <bill session="118" type="h" number="5378" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2023-10-03T15:46:31Z" status="Introduced in House">This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.</summary>
</bill>
